Chargement en cours...
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
BACKGROUND AND AIMS: Despite proven clinical efficacy of vedolizumab (VDZ) for inducing and maintaining remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC), subgroups of patients have no therapeutic benefit from anti-α4β7 integrin therapy with VDZ. Within this study, we aimed...
Enregistré dans:
| Publié dans: | Front Immunol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6090141/ https://ncbi.nlm.nih.gov/pubmed/30131801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01700 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|